Tag: panels

AB “Ignitis grupė” (hereinafter – the Group) informs that Vārme solar farm, controlled by its subsidiary UAB “Ignitis renewables” (hereinafter – Ignitis Renewables), has reached the commercial operation date (hereinafter – COD).

AB “Ignitis grupė” (hereinafter – the Group) informs that Vārme solar farm, controlled by its subsidiary UAB “Ignitis renewables” (hereinafter – Ignitis Renewables), has reached the commercial operation date (hereinafter – COD).

JCDecaux wins the exclusive advertising concession for Brussels Airport 

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI^® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.¹